Up to 40% of cancer patients experience clinically significant anxiety or depression — five times the rate of the general population. Emerging research on psychedelic-assisted therapy for this population shows response rates of 80–89%, with effects lasting years. This group is physician-led and psychiatrist-guided, with a clinical protocol designed specifically for the oncology population.